Lifitegrast
Lifitegrast, Xiidra (lifitegrast) is a small molecule pharmaceutical. Lifitegrast was first approved as Xiidra on 2016-07-11. It is used to treat dry eye syndromes in the USA. The pharmaceutical is active against integrin alpha-L.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Lifitegrast, Xiidra (discontinued: Lifitegrast)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lifitegrast
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XIIDRA | Bausch Health Companies | N-208073 RX | 2016-07-11 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lifitegrast | ANDA | 2023-11-13 |
| xiidra | New Drug Application | 2024-04-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| dry eye syndromes | — | D015352 | H04.12 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lifitegrast, Xiidra, Bausch And Lomb Inc | |||
| 11058677 | 2033-12-18 | DP | |
| 9085553 | 2033-07-25 | DP | |
| 8927574 | 2030-11-12 | DP | |
| 9353088 | 2030-10-21 | DP | |
| 9890141 | 2030-10-21 | DP | |
| 8168655 | 2029-05-09 | U-1880 | |
| 8367701 | 2029-04-15 | DP | U-1880 |
| 9447077 | 2029-04-15 | U-1900 | |
| 8084047 | 2026-05-17 | DS, DP | |
| 8592450 | 2026-05-17 | U-1880 | |
| 7314938 | 2025-03-10 | DS, DP | |
| 7745460 | 2024-11-05 | DS, DP | U-1880 |
| 7790743 | 2024-11-05 | U-1880 | |
| 7928122 | 2024-11-05 | DS, DP | |
| 9216174 | 2024-11-05 | DP | |
| 10124000 | 2024-11-05 | U-1900 | |
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dry eye syndromes | D015352 | — | H04.12 | 1 | 4 | 4 | 13 | 4 | 26 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | 4 | 4 | 10 | 4 | 22 |
| Eye diseases | D005128 | EFO_0003966 | H44 | 2 | 3 | 4 | 6 | 3 | 18 |
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | 2 | — | 3 |
| Cataract | D002386 | HP_0000518 | H26.9 | — | — | — | 1 | 1 | 2 |
| Keratoconjunctivitis | D007637 | — | H16.2 | — | — | 1 | 1 | — | 2 |
| Contact lenses | D003261 | — | — | — | — | — | 1 | — | 1 |
| Corneal diseases | D003316 | — | H18.9 | — | — | — | 1 | — | 1 |
| Meibomian gland dysfunction | D000080343 | — | H02.88 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Conjunctivitis | D003231 | HP_0000509 | H10 | — | 1 | — | — | — | 1 |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 1 | — | — | — | — | 1 |
| Macular edema | D008269 | — | — | 1 | — | — | — | — | 1 |
| Endophthalmitis | D009877 | — | — | 1 | — | — | — | — | 1 |
| Eye pain | D058447 | HP_0200026 | H57.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lifitegrast |
| INN | lifitegrast |
| Description | Lifitegrast is an N-acyl-L-alpha-amino acid obtained by formal condensation of the carboxy group of N-[2-(1-benzofuran-6-carbonyl)]-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid with the amino group of 3-(methanesulfonyl)-L-phenylalanine. Used for treatment of keratoconjunctivitis sicca (dry eye syndrome). It has a role as an anti-inflammatory drug and a lymphocyte function-associated antigen-1 antagonist. It is a L-phenylalanine derivative, a sulfone, a N-acyl-L-alpha-amino acid, a member of isoquinolines and a member of 1-benzofurans. |
| Classification | Small molecule |
| Drug class | antiasthmatics/antiallergics (not acting primarily as antihistamines): integrin antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1025967-78-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2048028 |
| ChEBI ID | — |
| PubChem CID | 11965427 |
| DrugBank | DB11611 |
| UNII ID | 038E5L962W (ChemIDplus, GSRS) |
Target
Agency Approved
ITGAL
ITGAL
Organism
Homo sapiens
Gene name
ITGAL
Gene synonyms
CD11A
NCBI Gene ID
Protein name
integrin alpha-L
Protein synonyms
antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide, CD11 antigen-like family member A, CD11a, integrin gene promoter, integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide), Leukocyte adhesion glycoprotein LFA-1 alpha chain, Leukocyte function-associated molecule 1 alpha chain, LFA-1 alpha, LFA-1A, lymphocyte function-associated antigen 1, alpha polypeptide
Uniprot ID
Mouse ortholog
Itgal (16408)
integrin alpha-L (Q3U159)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Xiidra – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Lifitegrast
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 719 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,388 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use